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Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy
(NACT) is a surrogate for outcome, but not necessarily conversion toBCTeligibility.We
sought to examine the impact of NACT on surgical decision making among HR+
patients.
Methods: Our IRB-approved breast cancer database was queried for patients who
underwent NACT, including the clinicopathologic data and surgeon’s pre- and post-
NACT assessment. Surgical conversion rate (SCR) was defined as patients ineligible for
BCT prior to NACT, who were given the choice following NACT.
Results: Among 289 patients, pCR rates were highest among patients with HER2-
enriched subtype (60%) and lowest in patients with luminal A disease (4%). Overall, the
BCT ratewas 41%,while 28%opted for bilateral mastectomy across subtypes. Despite
a low pCR, the SCR was still high (54%) among patients with the luminal A subtype.
Conclusion: Despite poor pCR rates, NACT still has potential to improve surgical
outcomes among hormone receptor positive patients. The surgical conversion rate is a
superior measure of the impact of NACT on surgical decision making than examining
BCT rates.
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1 | INTRODUCTION
Neoadjuvant chemotherapy (NACT) has become a hallmark for the
treatment of operable breast cancer by greatly expanding the pool of
potential breast conserving therapy (BCT) candidates by downstaging
tumors and permitting BCT in patients who would otherwise require a
mastectomy.1–3 Response to NACT has also emerged as a prognostic
sign. Patients with a pathologic complete response (pCR) to NACT
have an improved overall survival.3,4 This has dramatically altered our
approach to clinical trials of new therapeutics in breast cancer. By using
the pCR rate as a surrogate marker for NACT efficacy, clinical trials can
evaluate new therapeutic agents more rapidly than in the adjuvant
setting.
The use of NACT has also broadened our understanding of tumor
biology and differential response to treatment. Several studies have
identified molecular subtypes, based on gene expression profiles that
divide tumors into subgroups including luminal-like, basal-like, and
Her-2/neu over-expressing and that these subgroups are associated
with differences in outcome.5,6 As molecular profiling of each tumor is
not feasible or cost-effective, clinicians use hormone receptor status,
HER-2/neu expression, and either grade or Ki-67 expression to group
tumors into subtypes that approximate the molecular subtype
signatures.7 These histologic subtypes, based on information routinely
found in the pathology report from the diagnostic core biopsy, have
also been shown to correlate strongly with the tumor’s response to
NACT, specifically the pCR rate.
The correlation between histologic subtype and response has
allowed for a selective use of neoadjuvant chemotherapy. Patients
with hormone receptor positive disease, particularly in the absence of
Her-2/neu over-expression, have a low pCR rate.8 As such, there is
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often less enthusiasm for NACT on the basis that a pCR is less likely to
be achieved. However, from a surgical perspective, a pCR is not
necessary to permit BCT in a patient who would otherwise require a
mastectomy. There is less data regarding the degree of downstaging
based on histologic subtype. Most studies use the BCT rate as an
endpoint, but this metric is skewed by multiple factors outside of
response, andmay not be reflective of the true rate of conversion from
mastectomy to BCT. Herein, we sought to examine the percentage of
patients converted from requiring a mastectomy to being eligible for
BCT, regardless of their ultimate surgery, based on histologic subtype.
2 | METHODS
All patientswith biopsy-proven invasive breast cancer are presented at
the University of Michigan Comprehensive Cancer Center’s multidis-
ciplinary tumor board composed of surgeons, medical and radiation
oncologists, radiologists, pathologists, and associated support staff.
Once the patient has completed surgery, the details of these
discussions and the clinical and pathologic data are entered into our
prospective breast cancer database. With Institutional Review Board
approval, our database was queried for all adult female patients
21 years of age and older who underwent neoadjuvant chemotherapy
prior to surgery at theUniversity ofMichigan between 2002 and 2014.
Patients who had their pre-chemotherapy surgical evaluation at an
outside institution, or surgery at an outside institution, were excluded
from the study. Patients with inflammatory breast cancer or
documented stage IV disease were excluded. Patients who had
excision of the primary tumor prior to neoadjuvant therapy were also
excluded.
The database was queried for the pre-chemotherapy radiologic
and pathologic findings, operative details, and post-treatment
pathologic findings. A detailed review of the multidisciplinary visit
was conducted to determine the surgeon’s recommendations;
specifically, the suitability of patients to undergo BCT prior to
neoadjuvant chemotherapy and whether the patient would be a
eligible for BCT after neoadjuvant chemotherapy. Patients who were
not suitable candidates for BCT prior to neoadjuvant chemotherapy,
and had no contraindications to BCT after neoadjuvant chemotherapy
(widespread calcifications, multi-centric disease, contraindication to
radiation therapy), were classified as “Potential Downstage.” The
surgical conversion rate was defined as patients who were potential
downstages who were given the option of BCT after neoadjuvant
chemotherapy, regardless of the surgery they ultimately opted for.
This also included patients felt to be BCT candidates, who ultimately
underwent mastectomy secondary to inability to obtain negative
margins.
Patients were categorized by histologic subtype based on
estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu
expression using guidelines from the St. Gallen International Expert
Consensus 2011 and 2013, splitting Luminal B into two groups
(Luminal B- Her2- and Luminal B-like, Her2+) and using PR and Ki-67,
with one exception.9 At theUniversity ofMichigan, Ki-67 expression is
not routinely measured, so grade 3 was used in place of Ki-67 high.
Patients who were ER positive, PR positive, and Her-2/neu negative,
with grade 1 or grade 2 disease, were categorized as luminal A. Luminal
B (Her2 neg) included patients who were ER positive, HER2 negative,
and either grade 3 or PR low. Luminal B-like (Her2 pos) included
patients who were ER positive, HER2 overexpressed and any grade or
PR. HER2-enriched was defined as hormone receptor negative but
overexpressing Her-2/neu, while basal-type was defined as triple
negative.
3 | RESULTS
After excluding patients with stage IV disease, inflammatory breast
disease, and patients with no primary tumor in place prior to starting
neoadjuvant chemotherapy, we identified 289 patients who had their
pre-chemotherapy surgical assessment and subsequent surgery at the
University of Michigan between 2002 and 2014. Median age was 49
(range 22-88). Two-hundred and thirty-two were Caucasian (80%)
while 34 (12%) were African-American.
The pathologic features are summarized in Table 1. Themajority of
cases were invasive ductal carcinoma (88%), while 4% were lobular
carcinoma. The average tumor size prior to chemotherapy was 4.12,
with 60% being T2 tumors, 30% being T3 and 10% being T1. Over half
of the tumors, 163, were grade 3. Eighty-six (30%) were grade 2, while
only 20 (7%) were grade 1. Another 21 (7%) had unknown grades.
Estrogen receptor (ER) was positive in 50% of cases, while PR was
positive in 37%. Her-2/neu was over-expressed in 33%. Using
hormone receptor status, Her-2/neu over-expression, and grade 3
as an alternative to Ki67, patientswere stratified by histologic subtype.
This resulted in 53 (18%) tumors categorized as luminal A, 40 (14%)
categorized as Luminal B (Her2 neg), 53 (18%) as Luminal B-like (Her2
pos), 43 (15%) as HER2 enriched, and 100 (34%) as basal type (triple
negative).
Over this time period, pre-neoadjuvant chemotherapy nodal
staging, using both needle biopsy and SLN biopsy was performed on
the majority of patients. Needle biopsy, either FNA or core, was
performed in 146 (50%) of patients, while SLN biopsy was performed
in 119 (41%). Among the clinically node negative patients who
underwent SLN biopsy prior to neoadjuvant chemotherapy, 48 (40%)
were positive while 71 (60%) were negative. There were 25 patients
(9%) who did not have pathologic confirmation of their nodal status
prior to neoadjuvant chemotherapy; 11 were clinically node positive
while 14 were clinically node negative. Among the luminal A patients
undergoing neoadjuvant chemotherapy, over half (55%) were
documented as node positive prior to chemotherapy. This was a
lower percentage than the other subtypes; luminal B combined (71%),
HER2 enriched (71%), and basal (60%).
As expected, the complete pathologic response rate differed
greatly by histologic subtype. Overall, the pCR rate was 32%. Only
four patients (6%) with the luminal A subtype had a pCR. This was
greater for the luminal B (30%) and triple negative subtypes (40%).
The highest pCR rate was among patients with the HER2 enriched
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subtype at 62%. Looking at the surgery that patients underwent at
the completion of their chemotherapy, there is slightly less variation
between the subtypes. The breast conservation therapy (BCT) rate
overall was 41%, while 28% of patients opted to undergo bilateral
mastectomy. Table 2 breaks this down by subtype. Luminal A was
associated with the lowest rate of BCT (31%), while the triple
negative patients had the highest (47%). The decision to undergo
bilateral mastectomy was evenly distributed across subtypes.
We further characterized the “surgical conversion rate” by
eliminating patients who would or would not have been eligible for
BCT from the onset, and determining whether patients were eligible
for BCT after chemotherapy, regardless of what surgery they chose.
These are shown in Figure 1. Among luminal A patients, 35 of 53
(66%) were potential downstage candidates. Four patients were
deemed eligible for BCT prior to neoadjuvant chemotherapy, while
14 patients had a contraindication to BCT prior to neoadjuvant
chemotherapy (prior RT, multicentricity or widespread calcifica-
tions). Among these 46 patients who were not candidates for BCT
prior to neoadjuvant (potential downstage), 16 patients were
deemed poor candidates after neoadjuvant chemotherapy second-
ary to tumor size. There were 19 patients (54%) who were converted
to potentially BCT eligible. Among these patients, three opted for
unilateral or bilateral mastectomies regardless, and two patients who
were thought to be BCT eligible, ultimately underwent mastectomy
based on pathology. Using the same formula, the surgical conversion
rate was calculated for each of the subtypes. This surgical conversion
rate was 66% for the luminal B (Her2 neg) patients, 83% for the
luminal B-like (Her2 pos) patients, 85% for the HER2-enriched, and
78% for the basal subtypes.
With a mean follow-up of 5.84 years (three patients lost to follow-
up), the local recurrence rate was 5%; 2% for patients who had a
complete pathologic response (2 of 90, one luminal B-like one basal)
and 7% for patients who did not. Among patients who did not have a
pCR, the local recurrence rate was highest for the HER2-enriched (2 of
15, 12%) and basal (7 of 55, 11%). The local recurrence rate was 4% for
luminal A, 6% for Luminal B (Her2−), and 0% for Luminal B-like
(Her-2+).
4 | DISCUSSION
Neoadjuvant chemotherapy is the standard of care for patients with
locally advanced or inflammatory breast cancer and a hallmark of
therapy for women with operable breast cancer, allowing for a greater
population of patients to undergo breast conservation.10,11 It has also
allowed for downstaging of the axilla, allowing more women to avoid
axillary lymph node dissection.12–14 Although the delivery of
chemotherapy in the neoadjuvant setting has not demonstrated a
definitive survival benefit over adjuvant chemotherapy, there are other
potential advantages. One of these is the prognostic information
derived from the response to NACT, in particular the achievement of a
pathologic complete response (pCR), which is now considered to be a
surrogate marker of treatment efficacy.15 As such, many investigators
are examining predictors of pCRwhichmay allow for a better selection
of patients.
TABLE 1 Clinical and pathologic features of patients receiving
neoadjuvant chemotherapy
Age
Mean 48.9 years
Range 22-88
Race
White 232 (80%)
African-American 34 (12%)
Asian 10 (3%)
Island-Pacific 3 (1%)
Hispanic 3 (1%)
Other or unknown 8 (2%)
Tumor size
0-2cm 29 (10%)
2-5cm 176 (60%)
>5 83 (29%)
Occult 2 (1%)
Tumor histology
Ductal 257 (88%)
Lobular 12 (4%)
Other 19 (7%)
Unknown/unclassified 3 (1%)
Grade
1 20 (7%)
2 86 (30%)
3 163 (56%)
Unknown 21 (7%)
Nodal staging
Needle biopsy 146 (50%)
Pre-NACT SLN Bx 119 (41%)
No nodal staging 25 (9%)
Nodal status prior to NACT
Positive(clin or path) 199 (69%)
Path negative 71 (24%)
Clinically negative 20 (7%)
ER status
Negative 144 (50%)
Positive 144 (50%)
PR status
Negative 108 (37%)
Positive 182 (63%)
Her-2/neu status
Negative 194 (67%)
Positive 96 (33%)
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The predictive value of hormone receptor status, Her-2/neu over-
expression and tumor grade have been well established, and in the
absence of gene expression data, serve as surrogate classifications for
breast cancer subtypes.7,16 Several groups have demonstrated clear
differences in pCR rates by histologic subtype for breast cancer.8,17–21
While there are many studies looking at pCR rates by breast cancer
subtype, there are only a few studies looking at the impact on surgical
procedure. Boughey et al22 reported on the rates of BCT among
patients on the American College of Surgeons Oncology Group
(ACoSOG) Z1071 trial. They reported rates of BCT to be higher in
patients with triple-negative and HER-2 positive breast cancer (46.8%
and 43.0%, respectively) than inpatients with hormone-receptor
positive, HER2-negative disease (34.5%; P = 0.019). These remained
significant predictors of breast conservation on multivariable analysis,
along with older age, and lower tumor stage at presentation.
Simply measuring the percentage of patients who undergo
lumpectomy after neoadjuvant chemotherapy is a poor marker of
clinical response, as it does not reflect patients already eligible for BCT
prior to neoadjuvant chemotherapy and patients who would never be
eligible regardless of response. This is therefore an inaccurate measure
of the impact of NACT on surgical decision making. In the Z1071 trial,
BCS was more common in patients who presented with T0-T2 tumors
(52%) than in T3-T4 tumors (23%), which is not surprising as many of
these patients were candidates for BCS prior to chemotherapy.22 This
is impacted by histologic subtype as well. Patients with triple-negative
or HER-2/neu overexpressing tumors with T0-T2 tumors are more
likely to be considered for NACT, as chemotherapy is commonly
recommended regardless of tumor size or nodal status, than HR
+/HER-2− tumors, for whom chemotherapy may not be
recommended.
In addition to not reflecting the fraction of patients who were not
lumpectomy candidates prior to chemotherapy, simply measuring the
BCT rate also discounts the increasing percentage of patients who opt
for mastectomy after NACT, despite being down-staged. Increasingly,
women are opting for unilateral and bilateral mastectomy as an
alternative to BCT, and this continues to rise. For this reason, we
performed a more detailed analysis of our experience with NACT
among operable patients to measure the Surgical Conversion Rate;
defined as the percentage of patients who were converted from
requiring mastectomy to candidates for BCT. This eliminates those
patients who were eligible for BCT prior to NACT and those patients
who were never going to be eligible (for example patients with prior
TABLE 2 Final surgery by histologic subtype
N (%) BCT
Breast conservation rate
(%)
Unilateral
mastectomy
Bilateral
mastectomy
Bilateral mastectomy rate
(%)
Luminal A 53 (18) 15 31 19 15 31
Luminal B (HER−) 40 (14) 14 38 10 12 33
Luminal B-like (HER2
+)
53 (18) 20 37 18 15 28
HER2 enriched 43 (15) 18 39 15 10 23
Basal 100
(35)
47 47 23 25 26
Total 289 114 41 85 77 28
FIGURE 1 Pathologic and surgical response rates to neoadjuvant chemotherapy by histologic subtype
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radiation, multicentric disease or widespread calcifications). It also
incorporates those patientswho became eligible for BCT, but opted for
mastectomy. This requires a documented surgical opinion both before
and after chemotherapy. This data was often collected in the early
trials of neoadjuvant chemotherapy, where a primary endpoint was
breast conservation. However, as the pCR rate became the preeminent
endpoint, collecting this data became increasingly less common.
This information, rather than pCR, is critical to surgical decision
making as converting a patient to BCT-eligible may be obtained with a
partial response rather than a complete response. Partial response rate
alone, however, is inadequate as a partial response does not guarantee
BCS-eligibility. As opposed to pCR rates, the clinical response rates
may be less dependent on histologic subtype. In the Z1071 data,
changes in clinical tumor size between baseline and completion of
NACT were relatively similar across histologic subtypes, with clinical
partial responses in just over half of the patients.22 In our study, the
surgical conversion rate tells a much different story that the pCR or
BCT rate. The luminal A subtype had a significantly lower rate of pCR
(6%), and the lowest rate of BCT (32%). These numbers may suggest a
lack of benefit to NACT in this population, but the surgical conversion
rate was over 50%. While this is lower than the luminal B (Her2 neg)
(66%) and considerably lower than luminal B-like (83%) basal (78%) and
HER2 enriched (85%%), it demonstrates that a substantial number of
patientswith luminal A tumors realize a true clinical benefit fromNACT
despite the low likelihood of a pCR.
This does present a clinical catch-22 for patients who have large,
clinically node-negative luminal A tumors that without down-staging
would require a mastectomy. Despite the potential surgical benefit,
chemotherapy decisions, in either the adjuvant or neoadjuvant setting,
are based on preventing distant recurrence and improving survival.
Many of these patients are not clear candidates for chemotherapy, and
therefore, face a more complex decision algorithm. They could opt to
move forward with mastectomy, and reserve chemotherapy choices
until after the pathologic staging is complete, but many patients are
highly motivated for breast preservation. Another option would be for
neoadjuvant endocrine therapy. A meta-analysis of 20 randomized
clinical trials involving almost 3500 patients demonstrated that
neoadjuvant endocrine therapy was associated with response rates
similar to neoadjuvant chemotherapy.23 A third choice, for patients
motivated toward BCS, is to obtain more pre-NACT information.
Sentinel lymph node biopsy prior toNACT, aswas performed in several
patients in this trial, is less commonly utilized, as post-NACT SLN
biopsy more commonly allows for nodal down-staging and avoidance
of ALND. Another option is the use of genomic assays to identify
Luminal A patients who might be recommended for chemotherapy,
and thusmight opt to do this in the neoadjuvant setting.24 It is not clear
whether these assays can predict response to chemotherapy,
particularly with regard to surgical conversion, so more research in
this regard is warranted.25
In conclusion, while a pCR is significantly less common among
women with luminal A cancers, these patients still benefit from
neoadjuvant chemotherapy in regards to downstaging and eligibility
for breast conservation. Neoadjuvant chemotherapy is increasingly
used among BCT-eligible patients, and more BCT-eligible patients are
opting for unilateral or bilateral mastectomies. Therefore, BCT rates
are an inaccurate measure of the impact of NACT on surgical therapy.
Moving forward, clinical trials and outcome databases should
prospectively record BCT-eligibility both pre- and post-neoadjuvant
therapy so that the true surgical conversion rate, and associated
predictive factors, can be truly assessed.
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